Antibacterials. Volume II ([2018])

• Record Type: Book
• Further Information: Note: Jed F. Fisher, Shahriar Mobashery, Marvin J. Miller, editors ; with contributions by G. Allegretta [and others].
• Editors: Fisher, Jed F; Mobashery, Shahriar; Miller, Marvin J (Marvin Joseph)
• Contents: Intro; Preface; References; Contents; Nucleoside Natural Product Antibiotics Targetting Microbial Cell Wall Biosynthesis; 1 Nucleoside Antibiotics Targetting Translocase MraY on the Bacterial Peptidoglycan Biosynthetic Pathway; 1.1 Discovery of Nucleoside Natural Product Antibiotics and Their Mode of Action; 1.2 The Tunicamycin Group of GlcNAc-Tunicamine Nucleoside Antibiotics (Tunicamycins, Streptovirudins, and Corynetoxins); 1.3 The Mureidomycin Group of Ureidyl-Peptide Nucleoside Antibiotics (Mureidomycins, Pacidamycins, Napsamycins, and Sansanmyci... 1.4 The Liposidomycin Group of Liponucleoside Antibiotics (Liposidomycins and Caprazamycins)1.5 The Muraymycin Group of Lipo-Ureidylpeptide Nucleoside Antibiotics; 1.6 The Capuramycin Group of Caprolactam Nucleoside Antibiotics (Capuramycin and A-500359A); 2 Inhibition of Other Bacterial Phospho-Nucleotide Transferase Enzymes by Nucleoside Natural Product Analogues; 3 Nucleoside Antifungal Agents Targetting Fungal Chitin Synthase; 4 Future Prospects; References; The Cyclic Lipopeptide Antibiotics; 1 Introduction; 2 Colistin and the Polymyxins; 2.1 Background; 2.2 Mode of Action 2.3 Clinical Use2.4 Resistance; 3 Daptomycin and the Calcium-Dependent Antibiotics; 3.1 Introduction; 3.2 The CDA Lipodepsipeptides; 3.2.1 Background; 3.2.2 Mode of Action; 3.2.3 Clinical Use; 3.2.4 Resistance; 3.2.5 The CDA Lipopeptides; 4 Teicoplanin and the Lipoglycopeptides; 4.1 Background; 4.2 Mode of Action; 4.3 Clinical Use; 4.4 Resistance; 5 Ramoplanin and the Lipoglycodepsipeptides; 5.1 Background; 5.2 Mode of Action; 5.3 Clinical Development; 5.4 Resistance; 6 The Acyldepsipeptides; 6.1 Background; 6.2 Mode of Action; 6.3 Preclinical Development; 6.4 Resistance; 7 Bacitracin 7.1 Background7.2 Mode of Action; 7.3 Clinical Use; 7.4 Resistance; 8 Lotilibcin; 9 The Empedopeptins; 10 The Tridecaptins; 11 Semi-synthetic Lipopeptides Derived from Lantibiotics and Teixobactin; 12 Conclusions; References; Fully Synthetic Tetracyclines: Increasing Chemical Diversity to Combat Multidrug-Resistant Bacterial Infections; 1 Introduction; 2 Disubstituted Tetracyclines; 2.1 7, 9-Disubstituted Tetracyclines; 2.2 7, 8-Disubstituted Tetracyclines; 2.2.1 7-Substituted 8-Aminomethyltetracyclines; 2.2.2 7-Substituted 8-Heterocycle Tetracyclines; 3 Heterocyclines; 4 Polycyclines 5 ConclusionReferences; The Oxazolidinones; 1 Introduction; 2 Mechanism of Action Update; 3 Resistance Development Update; 4 Safety Profile; 5 Emerging Oxazolidinones of Interest; 5.1 Promising Oxazolidinone Clinical Prospects; 5.2 Recent Notable Structure-Activity Relationships; 5.3 New Oxazolidinone Chemistry; 6 Conclusions: What Now?; References; The Antifolates; 1 Folate Biosynthesis; 2 Dihydropteroate Synthase Inhibition: The Sulfonamides; 3 Thymidylate Synthase Inhibition; 3.1 Fluorouracil and Its Prodrugs; 3.2 Classical Antifolate TS Inhibitors
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2018
• Extent: 1 online resource, illustrations
• Subjects: 615.7/922; Antibacterial agents; MEDICAL / Pharmacology; Antibacterial agents; Chemistry; Medicinal Chemistry; Biochemistry, general; Organic Chemistry; Electronic books
• Languages: English
• ISBNs: 9783319708393; 3319708392
• Related ISBNs: 9783319708386; 3319708384
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (EBSCO, viewed July 13, 2018).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.